Skip to Content

FDA panel narrowly sides against experimental ALS drug


AP Health Writer

WASHINGTON (AP) — U.S. health advisers have narrowly ruled against an experimental drug for the debilitating illness known as Lou Gehrig’s disease. Wednesday’s vote by the Food and Drug Administration expert panel is a potential setback for patient groups who have lobbied for the medication’s approval for ALS for more than a year. A majority of panelists agreed with a negative review published by FDA scientists earlier in the week. Some said they hoped results of a larger study now underway would provide more evidence of the drug’s effectiveness. The panel’s vote is non-binding and the FDA will make its final decision by July.

Article Topic Follows: AP National Business

Jump to comments ↓

Associated Press


KIFI Local News 8 is committed to providing a forum for civil and constructive conversation.

Please keep your comments respectful and relevant. You can review our Community Guidelines by clicking here

If you would like to share a story idea, please submit it here.

Skip to content